Trial · NCT06620562
Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet
NCT06620562, Phase 4, Recruiting, Laval University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet. Trials, record NCT06620562. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06620562
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet
- NCT number
- NCT06620562
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 108 participants, estimated
- Lead sponsor
- Laval University
- Conditions
- Obesity; Drug, Obesity, Morbid
- Interventions
- Naltrexone/Bupropion, Placebo
- First posted
- 2024-10-01
- Last updated
- 2025-08-08
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight loss | baseline to 24 months | % Excess weight loss |
| Primary | Percentage of participant with an Excess Weight Loss above 50% | Baseline to 24 months | |
| Secondary | Resolution of associated comorbidities | Baseline to 24 months | Type 2 diabetes, hypertension and dislipidemia |
| Secondary | Improvement of Eating behaviors (Food Craving State Questionnaire) | Baseline to 24 months | Evaluates severity of cravings using a validated questionnaire. Minimum : 15; Maximum : 75; Higher scores mean a worse outcome. |
| Secondary | Improvement of Eating behaviors (Food Craving Trait Questionnaire) | Baseline to 24 months | Evaluates severity of cravings using a validated questionnaire. Minimum : 39; Maximum : 234; Higher scores mean a worse outcome. |
| Secondary | Decrease in food explicit and implicit wanting and liking food reward. | Baseline to 24 month | Decrease in food explicit and implicit wanting and liking food reward assessed by Leeds Food Preference Questionnaire using a computerized behavioural task |
| Secondary | Improvement in well-being, mood and Quality of Life (SF-36) | Baseline to 24 months | 36-item short form survey evaluating quality of life on a scale from 0 to 100, higher scores indicate better quality of life |
| Secondary | Improvement in well-being, mood and Quality of Life (QLaval) | Baseline to 24 months | Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7, higher scores indicate better quality of life |
| Secondary | Improvement in well-being, mood and Quality of Life (HAD questionnaire) | Baseline to 24 months | HAD questionnaire includes 14 rated items from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), obtaining two scores (maximum score of each score = 21). Higher scores indicate a worse outcome |
| Secondary | Gastro-intestinal side-effects | Baseline to 24-month | Gastro-intestinal side-effects assessed by GIQLI questionnaire on a scale from 0 to 144. Higher scores indicate better quality of life |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06620562
GET https://conductscience.org/api/trials/v1/NCT06620562/registered